OICHARTS
8 AMThe 8 AM report →

ALNY

Alnylam Pharmaceuticals, Inc. · XNAS · 131 sessions on record
$246.74▼ −7.33 · −2.9%from $254.07 the session before · Sep 30, 2026 close · end of day
Open
$253.68
High
$254.44
Low
$246.66
Day's range
$7.83.1% of the previous close
VWAP
$249.12close −0.96% from it
Volume, shares
1.04M0.69× the 20-session average
Traded, $
$260.2M
Trades
28.1K37 shares per trade
Previous close
$254.07−7.33 to the close
Market cap
$33.02Bat the close of Sep 30
Day range1% of the way up
$246.66$254.44
52-week range27% of the way up
$197.81 Jul 30$380.00 Jul 9

−35% from the high · +25% from the low

Options

No listed options on ALNY

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
ALNY close over the last 126 sessions, with S&P 500 rebased to the first close205.48297.87390.26axis spans 90%S&P 500ALNYApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 90 percent.

Quarterly results

consolidated · latest filed Jul 30, 2026 · SEC filings

Revenue $1.29B, +67% on a year earlier; profit $164.5M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of ALNY on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Jul 30$1.29B▲ +67%$164.5M—1.210.0%S&P 500 +0.7% · −0.7 pp
Mar 2026filed Jul 30——$206.0M——0.0%S&P 500 +0.7% · −0.7 pp
Dec 2025filed Feb 12$1.10B▲ +85%$153.1M—1.18—not reached
Sep 2025filed Oct 30$1.25B▲ +150%$251.1M—1.84—not reached
Jun 2025filed Jul 30$773.7M▲ +17%−$72.2M—-0.550.0%S&P 500 +0.7% · −0.7 pp
Mar 2025filed Jul 30$594.2M▲ +20%−$18.3M—-0.140.0%S&P 500 +0.7% · −0.7 pp
Dec 2024filed Feb 13$593.2M▲ +35%−$83.8M—-0.66—not reached
Sep 2024filed Oct 30$500.9M▼ −33%−$111.6M▼ −180%-0.87—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of ALNY on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$3.71B▲ +65%$313.7M—2.33
FY24to Dec 2024$2.25B▲ +23%−$278.2M—-2.18
FY23to Dec 2023$1.83B▲ +76%−$440.2M—-3.52
FY22to Dec 2022$1.04B▲ +23%−$1.13B—-9.30
FY21to Dec 2021$844.3M▲ +71%−$852.8M—-7.20

Fundamentals

consolidated · filings to Jun 2026 · close $246.74 on Sep 30

24 times book value, market cap $33.02B.

Valuation
Market cap
$33.02Bon Sep 30
Price to earnings
—
Trailing EPS
—
Price to book
24consolidated · balance sheet to Jun 2026
Book value a share
$10.12consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
81%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
134Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$774.7Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 190% of shares, FMR LLC the largest at 22%, Capital World Investors 17% and BlackRock, Inc. 16%, as filed for the quarter to Jun 2026.

Held by 13F managers
190%of shares outstanding
Shares held
253M+3.9% on Mar 2026 among managers filing both
Managers holding
744747 a quarter earlier
Largest holder
22%FMR LLC
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of ALNY
ManagerSharesOf outstandingValueChange on quarter
FMR LLC30M22%$9.05B+890K
Capital World Investors22.3M17%$6.71B+685K
BlackRock, Inc.21.8M16%$6.57B+926K
Capital Research Global Investors19.5M15%$5.87B+559K
VANGUARD PORTFOLIO MANAGEMENT LLC13.1M9.8%$3.94B+94.2K
VANGUARD CAPITAL MANAGEMENT LLC12.1M9.0%$3.63B+166K
Invesco Ltd.7.51M5.6%$2.26B+4.93M
STATE STREET CORP7.11M5.3%$2.14B+466K
JPMORGAN CHASE & CO5.35M4.0%$1.57B—
GEODE CAPITAL MANAGEMENT, LLC5.27M3.9%$1.58B−49.1K
Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

ALNY insider trades
InsiderTradeSharesPriceHeld after
PYOTT DAVID E IDirectorsold · Jun 1, 20261,175$298.913,316
PYOTT DAVID E IDirectorsold · Jun 1, 202617$302.651,582
PYOTT DAVID E IDirectorsold · Jun 1, 2026921$297.714,491
PYOTT DAVID E IDirectorsold · Jun 1, 2026495$300.721,599
PYOTT DAVID E IDirectorexercised · Jun 1, 20263,830$0.005,412
PYOTT DAVID E IDirectorsold · Jun 1, 20261,222$299.872,094
Arbuckle Stuart ADirectorgranted · May 20, 2026671$0.00671
Ausiello Dennis ADirectorgranted · May 20, 2026671$0.001,582
BRANDICOURT OLIVIERDirectorgranted · May 20, 2026671$0.001,446
HAMBURG MARGARET ADirectorgranted · May 20, 2026671$0.001,582

Corporate actions

exchange records

No corporate action on record for ALNY yet.

Price history

131 sessions on record · to Sep 30 · end of day

ALNY is +0.3% over 20 sessions against the S&P 500's +0.1%, 35% below its 52-week high, realised volatility 47% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $ALNY %S&P 500 %Difference pp
120 sessionssince Apr 9$321.28▼ −23%▲ +12%−35
60 sessionssince Jul 7$321.57▼ −23%▲ +2.0%−25
20 sessionssince Sep 1$246.10▲ +0.26%▲ +0.11%+0.15
5 sessionssince Sep 23$246.52▲ +0.09%▼ −0.67%+0.76
1 sessionsince Sep 29$254.08▼ −2.9%▼ −0.21%−2.7
Averages of the closeclose against each average
5-session average
$252.34close −2.2% from it
20-session average
$251.46close −1.9% from it
50-session average
$243.19close +1.5% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$8.33.4% of the close
Average day's range, 20
$9.53.8% of the close
Volume against 20 sessions
0.69×1.04M vs 1.46M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
47%≈ ±2.9% a session · moved more than that on 4 of 20
Realised volatility, 60
82%≈ ±5.2% a session · moved more than that on 7 of 60
Beta to S&P 500, 60
-0.65moved with S&P 500 on 34 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
10 up · 10 downof 20
Last 60 sessions
32 up · 28 downof 60
Best session, 250
▲ +8.7%Sep 2
Worst session, 250
▼ −28%Jul 30

Alnylam Pharmaceuticals, Inc. is held by

1 headlines on ALNY

latest Sep 28, 2026 · links go to the publisher

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 53% of reported volume on Sep 30, 2026, against 69% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
ALNY daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 2026184K345K53.3%
Sep 29, 2026229K311K73.7%
Sep 28, 2026317K483K65.5%
Sep 25, 2026298K410K72.7%
Sep 24, 2026291K388K75.0%
Sep 23, 2026327K482K67.9%
Sep 22, 2026342K432K79.2%
Sep 21, 2026388K504K77.0%
Sep 18, 2026460K626K73.5%
Sep 17, 2026270K360K75.0%

Filings

SEC EDGAR · newest first
ALNY SEC filings
FiledFormReport date
Sep 22, 20264Sep 19, 2026
Jul 30, 202610-QJun 30, 2026
Jul 30, 20268-KJul 30, 2026
Jun 3, 20264Jun 1, 2026
Jun 3, 20264Jun 1, 2026
Jun 3, 20263Jun 1, 2026
Jun 1, 2026144—
May 27, 20268-KMay 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 22, 20264May 20, 2026
May 14, 2026SCHEDULE 13G/A—
May 14, 2026SCHEDULE 13G/A—
May 14, 20264May 13, 2026
May 6, 2026SCHEDULE 13G/A—
Apr 30, 202610-QMar 31, 2026
Apr 30, 20268-KApr 30, 2026
Apr 29, 2026SCHEDULE 13G—
Apr 7, 20264Apr 2, 2026

About Alnylam Pharmaceuticals, Inc.

SEC and exchange records
Company
Alnylam Pharmaceuticals, Inc.
Exchange
XNAS
SEC CIK
1178670
Sessions on record
131
Price source
End of day · delayed
Computed
2 Oct, 01:04 am IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.